Navigation Links
Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals
Date:1/26/2009

FAIRFIELD, N.J., Jan. 26 /PRNewswire/ -- Medimetriks Pharmaceuticals announced today that the Company has entered into a Distributor Agreement with Perrigo Company (Nasdaq: PRGO), a leading manufacturer in the generic prescription marketplace, designating Perrigo as the Exclusive Authorized Distributor of generic versions of Medimetriks' branded products in the U.S. The agreement calls for Medimetriks to receive a percentage of Perrigo's Net Sales on the non-branded products, allowing Medimetriks to maximize its investment in its brands and maintain a revenue stream from the markets these brands create.

Founded in May, 2008, Medimetriks launched its first prescription brands in the 4th Quarter of 2008 to the Dermatology and Podiatry markets. These brands include Pacnex(TM) (7% Benzoyl Peroxide) Wash, a topical treatment for acne in a unique vehicle containing Aloe and Green Tea; Sumaxin(TM) (Sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads, a topical treatment for acne and rosacea also in a vehicle containing Aloe and Green Tea; and Uramaxin(TM) (45% Urea) Nail Gel, a treatment for diseased and damaged nails in a unique vehicle containing Menthol, Camphor and Eucalyptus Oil. The agreement also includes future products launched by Medimetriks.

"Our agreement with Perrigo represents a strategic opportunity for Medimetriks to leverage our brand assets in the non-branded marketplace," stated Bradley Glassman, President and CEO of Medimetriks. "We are pleased to work with one of the world's leading healthcare manufacturers and generic marketers, with a particular expertise in the topical generic market."

"We believe our relationship with Medimetriks will be a mutually beneficial one," stated Sharon Kochan, Executive Vice President of Perrigo. "Medimetriks' Management Team, having previously built Bradley Pharmaceuticals into an approximately $200 million gross revenue company, has a solid track record of success in building a branded pharmaceutical business in the markets they serve."

About Medimetriks Pharmaceuticals, Inc.

Medimetriks Pharmaceuticals develops, licenses and commercializes prescription skincare products primarily for the Dermatology and Podiatry marketplaces. The Company's mission is to enhance patient quality-of-life by providing innovative therapies that advance patient care.

The Company is located at 363 Route 46 West, Fairfield, NJ 07004-2402. Please visit the Medimetriks website at www.medimetriks.com, call (973) 882-7512 or fax (973) 882-7502.

Pacnex(TM) Wash is for external use only. Avoid contact with eyes, lips or mucous membranes. If severe irritation develops, discontinue use of Pacnex(TM) Wash. While using Pacnex(TM) Wash, patients should be advised to avoid unnecessary sun exposure. Please see full Prescribing Information available at www.medimetriks.com.

Sumaxin(TM) Cleansing Pads are contraindicated in persons with known or suspected hypersensitivity to sulfonamides or sulfur. Sumaxin(TM) Cleansing Pads are not to be used by patients with kidney disease. Although rare, topical sodium sulfacetamide may cause local irritation. Please see full Prescribing Information available at www.medimetriks.com.

Uramaxin(TM) Nail Gel is for external use only. Avoid contact with eyes, lips or mucous membranes. Transient stinging, burning, itching or irritation may occur and normally disappear on discontinuing the medication. Use as directed. Please see full Prescribing Information available at www.medimetriks.com.


'/>"/>
SOURCE Medimetriks Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Company Will Release Second Quarter Fiscal Year 2009 Results on February 3, 2009
2. Perrigo Company to Present at the 27th Annual JPMorgan Healthcare Conference
3. Perrigo Announces FDA Final Approval for Ibuprofen PM
4. Perrigo Settles Desloratadine Patent Litigation
5. Perrigo Acknowledges Settlement of NASACORT(R) AQ Nasal Spray Patent Litigation
6. Perrigo Announces FDA Tentative Approval for Ibuprofen PM
7. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
8. Perrigo Company To Present at the Merrill Lynch Global Pharmaceutical Conference
9. Perrigo Begins Shipments of Famotidine Complete to Customers Nationwide
10. Perrigo Company Announces Appointment of New Board Member
11. Perrigo Company to Present at The Oppenheimer & Co. Inc. 8th Annual Consumer Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President Joe A. ... a joint enrollment and degree completion agreement. The agreement, which begins with ... at FHU|Dickson. , The agreement allows students to be jointly admitted to ...
(Date:2/5/2016)... ... February 05, 2016 , ... In the fourth quarter of ... at the La Valencia Hotel in San Diego, California to discuss changes in ... year’s most outstanding franchise, walking away with the coveted David Wright Award of ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Boar’s Head ... just in time for this weekend’s Big Game. Take the stress out of your ... will keep your guests happy at every stage of the game. , “The key ...
(Date:2/5/2016)... ... 05, 2016 , ... Stuart Bentkover, MD, FACS is thrilled to ... the most effective tattoo removal today, Dr. Bentkover is the only doctor in Central ... the PicoSure has been approved by the Food and Drug Administration (FDA) as a ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a topic that ... the event they are experiencing an illness. Migraines are a severe form of a ... with migraines would not wish the pain on their worst enemy, the feeling can ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 5, 2016 --> ... report "Fetal (Labor & Delivery) and Neonatal Care Equipment ... Pulse Oximeter, Phototherapy/Jaundice Management Devices, CPAP, Capnograph, & Resuscitator) ... report studies the global market over the forecast period ... USD 6.28 Billion in 2015 and is poised to ...
(Date:2/4/2016)... For hospitals considering enrollment in the Federal ... the program, the Health Resources and Services Administration,s (HRSA) ... Mega-Guidance , could have significant impact on plans and ... 2016. Essential Insights , Daniel Neal, ... the Mega-Guidance,s key proposed changes, including a new requirement ...
(Date:2/4/2016)... , Feb. 4, 2016  SciClone Pharmaceuticals, Inc. ... it has entered into a settlement agreement with ... fully resolving the SEC,s investigation into possible violations ... the terms of the settlement agreement, SciClone has ... including disgorgement, pre-judgment interest and a penalty.  This ...
Breaking Medicine Technology: